These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 25790318)

  • 1. Central serous chorioretinopathy treatment with spironolactone: a challenge-rechallenge case.
    Ryan EH; Pulido CM
    Retin Cases Brief Rep; 2015; 9(3):235-8. PubMed ID: 25790318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SPIRONOLACTONE AS A THERAPEUTIC ALTERNATIVE FOR THE BULLOUS VARIANT OF CENTRAL SEROUS CHORIORETINOPATHY.
    Ramos-Yau EC; Muñoz-Domínguez E; Contreras-Mérida SP; Valencia-Londoño LM
    Retin Cases Brief Rep; 2020; 14(4):381-385. PubMed ID: 29595560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy.
    Cakir B; Fischer F; Ehlken C; Bühler A; Stahl A; Schlunck G; Böhringer D; Agostini H; Lange C
    Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2151-2157. PubMed ID: 27145785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy.
    Breukink MB; den Hollander AI; Keunen JE; Boon CJ; Hoyng CB
    Acta Ophthalmol; 2014 Sep; 92(6):e488-90. PubMed ID: 24698599
    [No Abstract]   [Full Text] [Related]  

  • 5. Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy.
    Bousquet E; Dhundass M; Lejoyeux R; Shinojima A; Krivosic V; Mrejen S; Gaudric A; Tadayoni R
    Am J Ophthalmol; 2019 Feb; 198():80-87. PubMed ID: 30308202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study.
    Bousquet E; Beydoun T; Zhao M; Hassan L; Offret O; Behar-Cohen F
    Retina; 2013; 33(10):2096-102. PubMed ID: 23719402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series.
    Salz DA; Pitcher JD; Hsu J; Regillo CD; Fineman MS; Elliott KS; Vander JF; Fischer DH; Spirn MJ
    Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):439-44. PubMed ID: 25970864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eplerenone in patients with chronic recurring central serous chorioretinopathy.
    Leisser C; Hirnschall N; Hackl C; Plasenzotti P; Findl O
    Eur J Ophthalmol; 2016 Aug; 26(5):479-84. PubMed ID: 26692062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spironolactone in the treatment of central serous chorioretinopathy - a case series.
    Herold TR; Prause K; Wolf A; Mayer WJ; Ulbig MW
    Graefes Arch Clin Exp Ophthalmol; 2014 Dec; 252(12):1985-91. PubMed ID: 25138605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY.
    Bousquet E; Beydoun T; Rothschild PR; Bergin C; Zhao M; Batista R; Brandely ML; Couraud B; Farman N; Gaudric A; Chast F; Behar-Cohen F
    Retina; 2015 Dec; 35(12):2505-15. PubMed ID: 26017871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new treatment approach - Eplerenone - in central serous chorioretinopathy - Case report.
    Cioboata M; Alexandrescu C; Hopinca CA; Pienaru MC; Merticariu A; Schmitzer S
    J Med Life; 2016; 9(1):92-94. PubMed ID: 27713772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH MINERALOCORTICOID ANTAGONISTS: A ONE-YEAR PILOT STUDY.
    Ghadiali Q; Jung JJ; Yu S; Patel SN; Yannuzzi LA
    Retina; 2016 Mar; 36(3):611-8. PubMed ID: 26405766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spironolactone versus observation in the treatment of acute central serous chorioretinopathy.
    Sun X; Shuai Y; Fang W; Li J; Ge W; Yuan S; Liu Q
    Br J Ophthalmol; 2018 Aug; 102(8):1060-1065. PubMed ID: 29089356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relation of the serum aldosterone level and central serous chorioretinopathy - a pilot study.
    Gong Q; Sun XH; Yuan ST; Liu QH
    Eur Rev Med Pharmacol Sci; 2017 Feb; 21(3):446-453. PubMed ID: 28239828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy.
    Yang D; Eliott D
    Semin Ophthalmol; 2017; 32(1):36-42. PubMed ID: 27929707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of efficacy of eplerenone for treatment of active central serous chorioretinopathy.
    Sadda SR
    Eye (Lond); 2020 Sep; 34(9):1489-1490. PubMed ID: 32042181
    [No Abstract]   [Full Text] [Related]  

  • 17. A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR).
    Rahimy E; Pitcher JD; Hsu J; Adam MK; Shahlaee A; Samara WA; Vander JF; Kaiser RS; Chiang A; Spirn MJ; Fineman MS
    Retina; 2018 May; 38(5):962-969. PubMed ID: 28426624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating the efficacy and safety of oral spironolactone in patients with central serous chorioretinopathy.
    Yavuz S; Balsak S; Karahan M; Dursun B
    J Fr Ophtalmol; 2021 Jan; 44(1):13-23. PubMed ID: 33279285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy.
    Pociej-Marciak W; Karska-Basta I; Ozog-Baran J; Kubicka-Trzaska A; Filemonowicz-Skoczek A; Romanowska-Dixon B
    Klin Oczna; 2016 Aug; 118(1):48-54. PubMed ID: 29715409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy.
    Pichi F; Carrai P; Ciardella A; Behar-Cohen F; Nucci P;
    Int Ophthalmol; 2017 Oct; 37(5):1115-1125. PubMed ID: 27757733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.